Industry News

Harrow relaunches Triesence

Harrow has relaunched Triesence, an FDA-approved, preservative-free corticosteroid used in eye surgeries and to treat severe ocular inflammation, according to a company press release. Triesence had been absent from the market for over 5 years, appearing on the FDA Drug Shortage List and facing 2 years of inventory depletion. “We...